Improved Operating and Net Losses
Operating loss was $2.3 million for Q1 2025, showing a 45% improvement over Q1 2024. Net loss was $3.1 million, a 29% improvement over the previous year.
Operating Expenses Reduction
Operating expenses were reduced by 33% to $7.7 million for the first quarter of 2025 compared to Q1 2024.
Positive Outlook for Future Growth
Strong pipeline for the second half of 2025, with anticipated cash flow positivity by year-end and potential growth in 2026.
Leadership Strengthening
Appointment of Dallas Scrip as Chief Operating Officer and President of MarpaiRx to enhance growth initiatives.
Launch of Empower Member Portal
Empower member portal rollout is on track, aiming to improve customer experience and operational efficiencies.